Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences Chairman & CEO Daniel O'Day reported an open-market sale of 10,000 shares of Common Stock on 2026-03-27 at an average price of $136.8162 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on 2025-02-28, with sale prices ranging from $136.51 to $137.22. Following this sale, he continues to directly hold 642,567 shares of Gilead Sciences common stock.
GILD reporting person Daniel O'Day filed a Form 144 reporting proposed sales of Common shares. The filing lists multiple dispositions by Mr. O'Day, with examples shown including a 02/05/2026 sale of 115,640 shares for $17,346,000 and a 01/23/2026 sale of 115,640 shares for $15,611,400. The notice names Morgan Stanley Smith Barney LLC as the broker.
Gilead Sciences Inc filing shows an amended Schedule 13G/A from The Vanguard Group reporting that, after an internal realignment, Vanguard and certain subsidiaries will report holdings separately and that The Vanguard Group beneficially owns 0 shares of Common Stock (0%).
The amendment explains the disaggregation is made in accordance with SEC Release No. 34-39538 and states related subsidiaries pursue the same investment strategies previously used; signature dated 03/26/2026.
Gilead Sciences, Inc. presents its 2026 annual meeting proxy, highlighting strong 2025 performance and several key voting items. Total 2025 product sales were $28.9 billion, with HIV product sales of $20.8 billion, representing 6% year-over-year growth. Base business revenues excluding Veklury were $28.0 billion, up nearly $1.2 billion, or 4%, and the non-GAAP operating margin was 45%. Gilead returned $5.9 billion to shareholders through $4.0 billion in dividends and $1.9 billion in share repurchases, contributing to a 37% total shareholder return for 2025.
The Board asks stockholders to elect nine directors, ratify Ernst & Young LLP as auditor, approve executive compensation on an advisory basis, and approve an amended and restated 2022 Equity Incentive Plan that adds 47,750,000 shares for issuance and extends the plan to March 11, 2036. The Board recommends “FOR” Proposals 1–4 and “AGAINST” three stockholder proposals on board chair independence, patent exclusivity reporting, and ESG/DEI compensation metrics.
Strategically, Gilead underscores HIV leadership, oncology and inflammation pipeline depth, and a planned $32 billion U.S. manufacturing and R&D investment through 2030, projected to generate $43 billion in U.S. economic value. The 2026 annual meeting will be held via virtual webcast on April 30, 2026.
Gilead Sciences executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of Gilead common stock in an open‑market transaction at a price of $144.23 per share. After this sale, she directly holds 131,779 shares of Gilead common stock.
The filing notes that this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 20, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at $144.23 per share in an open-market transaction. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024. Following this trade, he directly holds 179,191 shares of Gilead common stock.
Johanna Mercier reported sales of Common stock under a Section 144 notice. The filing records a sale of 28,000 shares on 02/17/2026 for $4,324,227.70 and a sale of 3,000 shares on 01/15/2026 for $372,930.00. The form also lists scheduled restricted stock grants dated 03/10/2024, 06/10/2024, and 09/10/2024 with quantities 426, 2037, and 537 respectively.
Andrew Dickinson reported sales of Common Stock, selling 3,000 shares on 02/17/2026 for $463,290.00 and 3,000 shares on 01/15/2026 for $372,930.00. The trades routed through Morgan Stanley Smith Barney LLC.
Gilead Sciences Chief Financial Officer Andrew Dickinson reported routine equity compensation activity. On March 10, 2026, he exercised restricted stock units into 6,469 shares of common stock and received a new grant of 9,590 restricted stock units, each representing one future share.
He was also granted 35,880 non-qualified stock options with an exercise price of $148.56 per share, expiring on March 10, 2036. Following the RSU exercise, 3,147 shares of common stock were withheld to cover tax obligations, leaving him with 182,191 common shares and 30,647 restricted stock units directly owned.
The RSU and option grants vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting in 6.25% quarterly installments, aligning his compensation with long-term shareholder value.